Abstract
Background: The COVID-19 pandemic as a public health crisis has led to a significant increase in mental health difficulties. Smoking is strongly associated with mental health conditions, which is why the pandemic might have influenced the otherwise decline in smoking rates. Persons belonging to socioeconomically disadvantaged groups may be particularly affected, both because the pandemic has exacerbated existing social inequalities and because this group was more likely to smoke before the pandemic. We examined smoking prevalence in a French cohort study, focusing on differences between educational attainment. In addition, we examined the association between interpersonal changes in tobacco consumption and educational level from 2018 to 2021. Methods: Using four assessments of smoking status available from 2009 to 2021, we estimated smoking prevalence over time, stratified by highest educational level in the TEMPO cohort and the difference was tested using chi2 test. We studied the association between interpersonal change in smoking status between 2018 and 2021 and educational attainment among 148 smokers, using multinomial logistic regression. Results: Smoking prevalence was higher among those with low education. The difference between the two groups increased from 2020 to 2021 (4.8–9.4%, p < 0.001). Smokers with high educational level were more likely to decrease their tobacco consumption from 2018 to 2021 compared to low educated smokers (aOR = 2.72 [1.26;5.89]). Conclusion: Current findings showed a widening of the social inequality gap in relation to smoking rates, underscoring the increased vulnerability of persons with low educational level to smoking and the likely inadequate focus on social inequalities in relation to tobacco control policies during the pandemic.
Original language | English |
---|---|
Article number | 1016 |
Pages (from-to) | 1-9 |
Number of pages | 9 |
Journal | BMC Public Health |
Volume | 23 |
DOIs | |
Publication status | Published - 30 May 2023 |
Bibliographical note
Funding Information:This research benefited from support from the French Institute for Public Health Research (IReSP) and the French Institute of Cancer (INCa), within the framework of the call for doctoral grants launched in 2020, under the project reference number “AAC-SPA-04”. The TEMPO cohort is supported by the French National Research Agency (ANR) (ANR-Flash COVID), the French Insititue for Public Health Research IReSP (TGIR Cohortes), the French Institute of Cancer (INCa), the French Inter-departmental Mission for the Fight against Drugs and Drug Addiction (MILDeCA), and the Pfizer Foundation. The TEMPO COVID-19 study is supported by the European Union’s Horizon 2020 research and innovation program RESPOND (funded under Horizon 2020 – the Framework Programme for Research and Innovation (2014–2020)). The content of this article reflects only the authors’ views, and the European Community is not liable for any use that may be made of the information contained therein.
Publisher Copyright:
© 2023, The Author(s).
Funding
This research benefited from support from the French Institute for Public Health Research (IReSP) and the French Institute of Cancer (INCa), within the framework of the call for doctoral grants launched in 2020, under the project reference number “AAC-SPA-04”. The TEMPO cohort is supported by the French National Research Agency (ANR) (ANR-Flash COVID), the French Insititue for Public Health Research IReSP (TGIR Cohortes), the French Institute of Cancer (INCa), the French Inter-departmental Mission for the Fight against Drugs and Drug Addiction (MILDeCA), and the Pfizer Foundation. The TEMPO COVID-19 study is supported by the European Union’s Horizon 2020 research and innovation program RESPOND (funded under Horizon 2020 – the Framework Programme for Research and Innovation (2014–2020)). The content of this article reflects only the authors’ views, and the European Community is not liable for any use that may be made of the information contained therein.
Funders | Funder number |
---|---|
ANR-Flash | |
French Insititue for Public Health Research IReSP | |
French Institute for Public Health Research | |
French Institute of Cancer | |
Pfizer Foundation | |
Horizon 2020 Framework Programme | |
Agence Nationale de la Recherche | |
Institut National Du Cancer | AAC-SPA-04 |
Institut National Du Cancer | |
Horizon 2020 | |
Institut pour la Recherche en Santé Publique |
Keywords
- COVID-19
- France
- Smoking behavior
- Social inequalities
- Tobacco